關於 Ginkgo Bioworks, Inc.
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.
Source: Wikipedia
總部27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON, MA 02210
成立時間2008
法律形式C Corporation
狀態營運中
專利289 項專利
INCREASED NITROGEN FIXATION USING BACTERIA WITH IMPROVED AMMONIA SECRETIONUS20260201315A1 · 2026
Scalable, mobile, and reconfigurable modules for processing biological and chemical materialsUS12674810B2 · 2026
關鍵數據
法律資訊
| 法定名稱 | Ginkgo Bioworks, Inc. |
|---|---|
| 法律形式 | C Corporation |
| SEC CIK | 1648827在 SEC EDGAR 上查看 ↗ |
| EIN | 26-3118890 |
| 登記地址 | 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON, MA 02210 |
| 狀態 | 營運中 |
來源: SEC EDGAR · 更新於 2026年10月15日
聯絡方式與連結
地點
27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON, MA 02210
這是你的公司嗎?
免費認領此頁面,即可新增標誌、產品、照片與職缺,並回覆評論。
認領此頁面